Clinical Trials Logo
  1. Home
  2. Dedifferentiated Liposarcoma
  3. NCT06389799

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) — PERELI  

Dedifferentiated Liposarcoma Clinical Trial

Official title:
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma

Clinical Trial Summary

Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improved by combining it with other types of tumor drugs. Medicines that inhibit signaling via the FGF receptor, so-called FGFR inhibitors, have shown a tumor-slowing effect in DDLPS in early studies. FGFR inhibitors can also induce changes that make the tumor more available to treatment with immunotherapy. The study aims to investigate whether the combination of an FGFR inhibitor, pemigatinib, with a PD-1 inhibitor, retifanlimab can provide a tumor-slowing effect in patients with advanced DDLPS who have progressed on first-line treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06389799
Study type Interventional
Source Lund University Hospital
Contact Helena Nyström, MD
Phone +46 46 17 75 20
Email helena.nystrom@skane.se
Status Not yet recruiting
Phase Phase 2
Start date May 7, 2024
Completion date December 31, 2028
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03307616 - Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery Phase 2
Completed NCT01913652 - Ph II Cabazitaxel DD Liposarcoma Phase 2
Recruiting NCT05886634 - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Phase 2
Completed NCT06115681 - Real-world Study of Dedifferentiated Liposarcoma Patients in China
Active, not recruiting NCT02846987 - Study of Abemaciclib in Dedifferentiated Liposarcoma Phase 2
Terminated NCT04979442 - Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma Phase 3
Completed NCT02606461 - Selinexor in Advanced Liposarcoma Phase 2/Phase 3
Active, not recruiting NCT04242238 - Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Phase 1
Withdrawn NCT00969917 - Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Phase 2
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Terminated NCT03604783 - Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05496569 - TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma Phase 2